precision medicine has the potential to change the way we think about, identify and manage cancer care. the impact on both clinical research and patient care will grow as our understanding and technologies improve and personalised medicine and biomarkers will transform the delivery of cancer care to benefit both patients and cancer care systems.

the european commission defined [2015] personalised medicine as “a model of medicine that uses the molecular profile [phenotypes and genotypes] for tailoring the right therapeutic strategy for the right person at the right time, and | or to determine the predisposition to disease and | or to deliver timely and targeted prevention” working in collaboration, we can greatly improve access to personalised medicines and biomarkers, with a flexible regulatory framework that accelerates access, encouraging policies that invest in and support the use of personalised medicines and biomarkers, and educating on the potential effectiveness and efficiency personalised medicine and biomarkers can make in our health care system.

precision medicine is rapidly having an impact on how drugs are discovered and developed; how patients are diagnosed and treated; and how health care delivery is channeling its resources to maximize patient benefits. personalised medicine is having an important impact in clinical care, the great potential to improve the quality of patient care and to help contain health care costs and it should be directed at individual patients through the practice of medicine rather than through regulatory action.